Compare Stocks

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMS Adamas Pharmaceuticals	$8.22	$8.17	$4.02 ▼ $9.15	$376.37M	2.82	692,487 shs	N/A
BLU BELLUS Health	$14.74	$14.62	$6.38 ▼ $14.76	$1.87B	0.19	3.08 million shs	3.45 million shs
CYAD Celyad Oncology	$0.60	$0.67	$0.46 ▼ $3.07	$15.91M	N/A	N/A	3,009 shs
GNPX Genprex	$2.30 +3.6%	$3.67	$2.18 ▼ $45.20	$4.39M	-0.61	73,821 shs	15,649 shs
NERV Minerva Neurosciences	$2.51 +0.4%	$4.07	$2.26 ▼ $13.49	$17.55M	0.21	106,030 shs	4,814 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMS Adamas Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BLU BELLUS Health	0.00%	0.00%	0.00%	0.00%	+2.08%
CYAD Celyad Oncology	0.00%	0.00%	0.00%	0.00%	-4.76%
GNPX Genprex	0.00%	-20.50%	-34.62%	-73.56%	-94.42%
NERV Minerva Neurosciences	+1.62%	-1.18%	-5.28%	-66.67%	-17.97%

New crypto project uncovers 2,050% in 65 days (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BLU BELLUS Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	4.1923 of 5 stars	3.5	5.0	0.0	4.7	0.6	0.8	1.3
NERV Minerva Neurosciences	3.0972 of 5 stars	3.0	3.0	0.0	4.6	2.0	0.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A
BLU BELLUS Health	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A
GNPX Genprex	3.00	Buy	$10.00	334.78% Upside
NERV Minerva Neurosciences	2.00	Hold	$11.00	338.25% Upside

Current Analyst Ratings

Latest GNPX, NERV, BLU, ADMS, and CYAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2024	GNPX Genprex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/25/2024	GNPX Genprex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$10.00
2/27/2024	NERV Minerva Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$11.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMS Adamas Pharmaceuticals	$74.46M	5.05	N/A	N/A	($0.47) per share	-17.49
BLU BELLUS Health	$15K	124,613.93	N/A	N/A	$3.09 per share	4.77
CYAD Celyad Oncology	$110K	144.65	N/A	N/A	$0.20 per share	3.00
GNPX Genprex	N/A	N/A	N/A	N/A	$4.99 per share	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($4.07) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMS Adamas Pharmaceuticals	-$57.40M	-$1.70	N/A	N/A	N/A	-71.11%	N/A	-42.96%	N/A
BLU BELLUS Health	-$76.08M	-$0.72	N/A	N/A	N/A	-578,586.63%	-24.27%	-23.14%	N/A
CYAD Celyad Oncology	-$9.14M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	-$30.86M	-$24.80	N/A	N/A	N/A	N/A	-245.62%	-185.50%	5/27/2024 (Estimated)
NERV Minerva Neurosciences	-$30M	-$4.65	N/A	N/A	N/A	N/A	N/A	-50.27%	5/20/2024 (Estimated)

Latest GNPX, NERV, BLU, ADMS, and CYAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/22/2024	Q4 2023	NERV Minerva Neurosciences	-$0.88	-$1.19	-$0.31	-$1.19	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMS Adamas Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BLU BELLUS Health	N/A	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMS Adamas Pharmaceuticals	21.25	4.53	4.17
BLU BELLUS Health	N/A	33.42	33.42
CYAD Celyad Oncology	N/A	N/A	N/A
GNPX Genprex	N/A	2.31	2.31
NERV Minerva Neurosciences	N/A	12.57	12.58

Ownership

Institutional Ownership

Company	Institutional Ownership
ADMS Adamas Pharmaceuticals	69.97%
BLU BELLUS Health	90.37%
CYAD Celyad Oncology	N/A
GNPX Genprex	14.05%
NERV Minerva Neurosciences	34.56%

Insider Ownership

Company	Insider Ownership
ADMS Adamas Pharmaceuticals	18.90%
BLU BELLUS Health	24.17%
CYAD Celyad Oncology	0.94%
GNPX Genprex	11.54%
NERV Minerva Neurosciences	6.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMS Adamas Pharmaceuticals	138	45.79 million	37.13 million	Optionable
BLU BELLUS Health	74	126.81 million	96.16 million	Not Optionable
CYAD Celyad Oncology	95	26.52 million	26.28 million	Not Optionable
GNPX Genprex	31	1.91 million	1.69 million	Optionable
NERV Minerva Neurosciences	9	6.99 million	6.55 million	Not Optionable

GNPX, NERV, BLU, ADMS, and CYAD Headlines

Source	Headline
	Minerva Neurosciences (NASDAQ:NERV) Shares Pass Below 200 Day Moving Average of $5.76 americanbankingnews.com - April 12 at 3:24 AM
	Crestwood softball doomed by defensive miscues in loss to Minerva weeklyvillager.com - April 4 at 8:40 PM
	Prairie voles display signs of human-like depression, show promise as animal model msn.com - April 4 at 8:40 PM
	Andreas Martinos firm Minerva Marine sells aframax tanker after newbuilding orders tradewindsnews.com - April 4 at 7:34 AM
	Here Comes Rutgers Day rutgers.edu - April 1 at 10:14 AM
	New track and field season gives Minerva sprinter Kyleigh Lippincott a fresh start msn.com - March 31 at 2:50 AM
	Irish singer/songwriter Enda Reilly to perform in Minerva on April 12 reviewonline.com - March 28 at 9:43 PM
	Reuben Norman litter picking at Minerva Primary School somersetcountygazette.co.uk - March 28 at 9:43 PM
	F\|T: The FinTech Times – Minerva chases anti-money laundering big leagues betakit.com - March 18 at 7:55 PM
	BMS completes $14bn takeover of Karuna pharmaphorum.com - March 18 at 7:55 PM
	Minerva Porras, 86 riverheadlocal.com - March 17 at 12:39 PM
	Social factors taskforce launches guidance with support from Minerva manifest.co.uk - March 15 at 1:01 PM
	Potts Point homelessness encampment moved on from Minerva-Metro Theatre site msn.com - March 14 at 9:56 PM
	Minerva Named "One to Watch" in Chartis Financial Crime and Compliance 50 Rankings tmcnet.com - March 14 at 9:56 PM
	Renovated Manti Temple, preserved Minerva Teichert murals ready for 3-week public open house msn.com - March 13 at 10:46 PM
	Potts Point homelessness encampment moved on by Minerva-Metro Theatre developer owners news.com.au - March 13 at 10:46 PM
	Minerva Named Top AI & Data Product in the 2024 Product Awards tmcnet.com - March 13 at 12:45 PM
	Acadia pulls trials of pimavanserin after schizophrenia fail pharmaphorum.com - March 12 at 8:51 AM
	FDA Delays Approval of Roluperidone for Schizophrenia Treatment medindia.net - February 29 at 3:38 PM
	FDA Denies Approval of Roluperidone for Negative Symptoms of Schizophrenia empr.com - February 28 at 6:41 PM
	Minerva slumps as FDA finds fault with schizophrenia filing pharmaphorum.com - February 28 at 8:40 AM
	Minerva hit with FDA rejection for schizophrenia symptom drug pharmaceutical-technology.com - February 28 at 8:40 AM
	Hold Rating on Minerva Neurosciences Amid FDA Setbacks and Financial Constraints markets.businessinsider.com - February 27 at 7:53 PM
	Minerva schizophrenia drug rejected by FDA finance.yahoo.com - February 27 at 2:50 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 High Short Interest Stocks Getting Squeezed With Upside To Go
April 5, 2024 9:25 AM
View 5 High Short Interest Stocks Getting Squeezed With Upside To Go
Buy the Dip in Netflix Stock, It Won’t Last Long
April 19, 2024 8:32 AM
View Buy the Dip in Netflix Stock, It Won’t Last Long
Comprehensive PepsiCo Stock Analysis
April 18, 2024 12:05 PM
View Comprehensive PepsiCo Stock Analysis

All Headlines

Company Descriptions

Adamas Pharmaceuticals

NASDAQ:ADMS

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

BELLUS Health

NASDAQ:BLU

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Celyad Oncology

NASDAQ:CYAD

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Genprex

NASDAQ:GNPX

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Minerva Neurosciences

NASDAQ:NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial